Abstract
Discontinuation or poor adherence to antipsychotics in patients with schizophrenia may lead to relapses. Compared with daily administered antipsychotics (e.g., paliperidone extended-release (ER)), long-acting injectable antipsychotics (LAI) can improve medication adherence, resulting in a lower risk of relapse. Paliperidone palmitate, a new form of LAI, can be administered monthly (PP1M), three monthly (PP3M), or six-monthly (PP6M). While proven effective in improving compliance, the economic value of administering this high-cost treatment is unknown.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
